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Abstract The production of high affinity, class switched antibodies produced by B cells hinges on
the effective differentiation of T follicular helper (Tfh) cells. Here we define conditions specifically
enhancing Tfh differentiation and providing protection in a model of influenza infection. Tfh
responses were associated with prolonged antigen presentation by dendritic cells (DCs), which
maintained T cell/DC interactions into stage 3 (>72 hr) of activation. Blocking stage 3 interactions
ablated Tfh generation, demonstrating a causal link between T cell-DC behaviour and functional
outcomes. The current data therefore explain how duration of antigen presentation affects the
dynamics of T cell-DC interactions and consequently determine Tfh cell differentiation in the
developing immune response.
DOI: 10.7554/eLife.06994.001
Introduction
Following stimulation via the TcR, selective differentiation of T helper cell subsets is dependent on
transcription factors, with Bcl-6 being responsible for T follicular helper (Tfh) cell differentiation
(Johnston et al., 2009; Choi et al., 2011) and antagonism of other T cell phenotypes (Th1, Th2,
Th17). Gene knockout studies in mice have revealed the requirement for CD28 mediated-
costimulation in the upstream control of Tfh differentiation (Linterman et al., 2009), with
subsequent signalling through inducible T cell costimulator (ICOS) involved in consolidation of
differentiation (Crotty, 2011; Xu et al., 2013). The mechanisms controlling the induction of this
differentiation program are less clear, a role for the cytokines IL-6 and IL-21 and subsequent
signalling via STAT3 have been implicated (Nurieva et al., 2008), while other studies indicate that
the strength and duration of the T cell receptor (TCR) signal itself is the major factor determining
effector cell differentiation to Tfh (Fazilleau et al., 2009; Tubo et al., 2013). Using well defined and
controlled conditions that preferentially induce Tfh responses in vivo, we have therefore adopted
a reductionist approach to determine which of these factors are important in the differentiation of
this subset in vivo.
A variety of particle formulations, including alum, emulsions and liposomes have received sustained
interest as vaccine adjuvants for over 80 years (Brewer, 2006; Xiang et al., 2006; De Temmerman
et al., 2011). Their ability to affect the availability of antigen and antigen presentation has frequently
been linked to their impact on the development of T cell responses (Constant and Bottomly, 1997),
but causal evidence has been absent. More recently, studies have suggested that the use of
nanoparticles as adjuvants can selectively induce Tfh responses (Moon et al., 2012). Clearly selective
differentiation of Tfh effector cells has implications in vaccine design and pathogen control as for the
majority of vaccines the principal effector mechanism induced is production of high affinity, class
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switched antibodies by B lymphocytes. Here we employ defined antigen particles to selectively induce
Tfh cells and antibody responses and show that increased duration of antigen presentation and
subsequent T cell/dendritic cell (DC) interactions are associated with Tfh induction. The functional
significance of these late stage (72 hr) interactions in T cell differentiation was demonstrated by
blockade of T/DC interactions in vivo. These studies demonstrate that by manipulating the form of
antigen delivered late stage antigen presentation by DC and their interaction with T cells can be
controlled to drive Tfh differentiation in vivo.
Results
Antigen size impacts on protective humoral immunity
In the present study, we employed polystyrene nanoparticles due to their inert nature, defined size,
narrow polydispersity, and surface functionalisation allowing covalent linkage of antigen to their
surface. Polystyrene nanoparticles do not induce ERK activity or subsequent activation of conventional
inflammatory pathways in DC (Karlson Tde et al., 2013). Our study focused on polystyrene
nanoparticle sizes able to drain freely to the LN (Manolova et al., 2008). Carbodiimide-mediated
coupling of antigens was highly controlled, such that only particle size and physically dependent
parameters (surface area, antigen molecules per particle) varied between immunisation conditions; all
other conditions, antigen dose, mass of particles, and antigen density were consistent between
40 nm and 200 nm particle immunisations (Table 1). Consequently, immunisations with equivalent
quantities of protein were not associated with any confounding difference in total antigenic mass and
a single variable, particle size could be tested for its impact on antigen specific immune responses.
Initial experiments investigating the effect of particle size on antibody responses revealed that
immunisation of mice with Ag covalently linked to 200 nm particles induced significantly higher
amounts of specific IgG1 and IgG2c than smaller particles or soluble Ag (Figure 1A,B).
1000 nm particles failed to induce an antibody response, potentially due to a failure in uptake by
APCs and/or ability to drain to the LN. Subsequent studies thus focussed on the significance and
eLife digest The immune system protects the body from infections, cancer and other diseases.
Invading microbes and cancerous cells exhibit proteins that are not normally found in the healthy
cells of the body. Fragments of these molecules—known as antigens—may be detected by the
immune system, which can then respond by producing antibodies and other responses that try to
destroy the threat.
Antibodies are produced by one type of immune cell (known as B cells) with the help of other cells
called follicular helper T (Tfh) cells. During an immune response, Tfh cells form from ‘naı¨ve’ T cells that
have not encountered an antigen before. This process has several stages and is activated when the
naı¨ve T cells interact with antigens that are displayed on the surface of dendritic cells and other
immune cells. However, it is not clear exactly how this process works.
Here, Benson et al. studied the formation of Tfh cells in mice in response to antigens of different
sizes. The experiments show that the dendritic cells displayed larger antigens for longer periods of
time than they displayed the smaller antigens. Both the small and large antigens allowed dendritic
cells to interact with T cells. However, only the dendritic cells that displayed the larger antigens
maintained the interaction with T cells for longer periods of time (into the last stage of Tfh cell
formation). This enhanced the production of Tfh cells, which boosted the production of antibodies
against the antigens to generate immunity to infection.
Further experiments found that blocking the interaction between dendritic cells and T cells during
the final stage of Tfh cell formation reduced the production of Tfh cells. Benson et al.’s findings show
that the length of time that dendritic cells present antigens on their surface affects the production of
Tfh cells and subsequent immune responses. Since Tfh cells are critical to the formation of long-
lasting immunity against a virus, these findings could aid efforts to develop more effective vaccines
against influenza and other diseases.
DOI: 10.7554/eLife.06994.002
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processes by which the 200 nm particles were
able to support this antibody response, in
comparison to smaller particles (40 nm) and
soluble antigen that did not.
The functional importance of the observed
antigen specific antibody response was evalu-
ated in a murine influenza virus infection model
where antibodies to the hemagglutinin (HA)
component of influenza virus are important to
protective immunity (Murphy et al., 1982;
Gerhard, 2001), blocking viral attachment and
fusion of the viral and host cell membrane
(Knossow and Skehel, 2006). Three weeks after
immunisation with HA linked to 200 or
40 nm particles, emulsified in complete Freund’s
adjuvant (CFA) or as soluble protein, mice were
challenged intranasally with influenza A virus
(H1N1; A/WSN/1933 [WSN]). Protection from
infection was determined by weight loss (Figure 1C). While mice immunised with
200 nm HA-particles were protected from virus induced pathology, significant weight loss was
observed in groups immunised with 40 nm HA-particles, similar weight loss to that observed in
unimmunised or soluble HA treated mice.
Table 1. Comparison of particle conjugates
Particle size 40 nm 200 nm
Antigen dose/mouse 100 μg 100 μg
Antigen molecules/mouse 1.3 × 1015 1.3 × 1015
Latex dose/mouse 100 μg 130 μg
Number of particles/mouse 1.4 × 1012 2.9 × 1010
Antigen molecules/particle 1000 20,000
Surface area/particle 5024 nm2 125,600 nm2
Antigen density 1 per 5 nm2 1 per 6 nm2
Data shows an example of a typical carbodiimide-
mediated conjugation of ovalbumin to either 40 or 200
nm. Various parameters relating to a typical s.c.
immunisation with 100 μg of protein are shown.
DOI: 10.7554/eLife.06994.003
Figure 1. Immunisation with antigen loaded 200 nm particles induces elevated IgG and can provide protective
immunity to influenza virus infection. Mice were immunised s.c. in the scruff with 100 μg of ovalbumin (OVA) alone
or conjugated to 20 nm, 40 nm, 100 nm, 200 nm or 1000 nm particles. 14 days later, serum was tested by ELISA for
anti-OVA-IgG2c (A) and anti-OVA-IgG1 (B). Data show the mean (−) absorbance (405 nm) at a dilution of 1 in 200
with the five experimental animals per group (′) ***p < 0.001 comparing to the PBS group. To assess functional
responses, C57BL/6 mice were immunised s.c. with 50 μg of hemagglutinin (HA) alone, conjugated to 40 or
200 nm particles, or emulsified with complete Freund’s adjuvant (CFA). Weight changes were then monitored
following intranasal infection with 300 PFU of influenza A virus (WSN) (C). Data shows the mean of five experimental
animals per group ± standard deviation ***p < 0.001 comparing 200 nm group to 40 nm group.
DOI: 10.7554/eLife.06994.004
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Antigen size influences the development of Tfh and B cell responses
To delineate the mechanisms that allow particle size to control antibody responses, we employed an
established adoptive transfer model (Garside et al., 1998). Antigen specific CD4+ T cells and B cells
were co-transferred into congenic recipients then immunised with 130 μg of ovalbumin (OVA)-hen
egg lysozyme (HEL) conjugate alone, in CFA or bound to 40 nm or 200 nm particles. Analysis of
serum samples collected 10 days post immunisation revealed OVA-HEL conjugated to
200 nm particles induced significant levels of serum anti-HEL-IgMa, whereas antigen conjugated
to 40 nm particles did not (Figure 2A). Similarly, antigen conjugated to 200 nm particles induced
greater expansion of antigen-specific IgMa+ MD4 B cells than challenge with 40 nm particles 7 days
post immunisation (Figure 2B). Enhanced expression of germinal centre (GC) markers (GL7 and
FAS) following immunisation with 200 nm OVA-HEL particles compared with 40 nm OVA-HEL
particles was also evident (Figure 2C,D). Conventional GC responses are dependent on activated,
antigen-specific CD4+ T cells (Owens and Zeine, 1989; Nutt and Tarlinton, 2011), suggesting that
Figure 2. Immunisation with antigen loaded 200 nm particles enhances B cell expansion and germinal centre (GC) B
cell responses. To dissect the cellular responses in detail, MD4 BcR transgenic (Tg) B cells and OT-II TcR Tg T cells
and were adoptively transferred into C57BL/6 recipients. Mice were then challenged with OVA-hen egg lysozyme
(HEL) conjugated to 40 nm or 200 nm particles. Challenges with PBS, OVA-HEL alone or in CFA were included as
negative and positive controls. Day 10 serum samples were assayed by ELISA to determine anti-HEL-IgMa levels (A).
Expansion of B220+IgMa+ MD4 B cells in popliteal LNs was assessed by flow cytometry 7 days post challenge (B).
Development of GC B cell responses was determined by examining GL7 and FAS expressing by MD4 B220+ cells (C).
Representative staining of GC markers GL7 and FAS are also shown (D). Panels show mean value and five individual
animals in a representative experiment of 3.
DOI: 10.7554/eLife.06994.005
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different particles could induce changes in the magnitude or phenotype of the resulting T cell
response. However, immunisation with OVA-HEL conjugated to either 40 nm or 200 nm particles
could equally increase the proportion and number of antigen specific OT-II T cells in vivo
(Figure 3A,B), consistent with a previous report (Gengoux and Leclerc, 1995). This implied that
particle size induced a qualitative rather than quantitative difference in T cell response, favouring
generation of the Tfh subset of T cells that have been defined as supporting B cell responses and
GC formation (Ma et al., 2012). Analysis of Tfh markers CXCR5, PD-1, ICOS and SLAM by
adoptively transferred OT-II T cells demonstrated the percentage and number of antigen specific
cells differentiating into Tfh cells was very low at day 5 post immunisation with soluble antigen or
antigen conjugated to 40 nm particles (Figure 3C–E). However, a significant proportion of OT-II
Figure 3. 200 nm particles induce T follicular helper (Tfh) differentiation. MD4 BcR Tg B cells and OT-II TcR Tg T cells
and were adoptively transferred into C57BL/6 recipients. Mice were then challenged with OVA-HEL conjugated to
40 nm or 200 nm particles. Challenges with PBS, OVA-HEL alone or in CFA were included as negative and positive
controls. CD4+DsRed+OT-II cell expansion in LNs 5 days post challenge (A, B). These were defined as Tfh cells when
being PD-1+ and CXCR5+ (C, D). Cells were also confirmed as being both ICOS+ and SLAM+ (E). Panels show mean
value and five individual animals in a representative experiment of 3.
DOI: 10.7554/eLife.06994.006
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T cells were CXCR5+PD-1+ following challenge with OVA-HEL conjugated to 200 nm particles
(Figure 3C–E). Changing a single physical characteristic of the immunising antigen selectively
enhanced Tfh differentiation without impacting on the magnitude of T cell response, providing an
excellent platform to dissect how external stimuli can contribute to Tfh development in vivo.
Antigen size can determine duration of peptide/MHCII presentation LN
APCs
Adjuvants are thought to influence the availability of antigen in vivo and the kinetics of antigen
presentation influence consequent CD4+ T cell proliferative, effector and memory responses (Obst et al.,
2005, 2007; Celli et al., 2007). By covalently linking a traceable antigen, EαGFP (Pape et al., 2007), to our
particles we were able investigate the impact of particle size on peptide/MHCII presentation in vivo.
Immunisation with 40 nm particles resulted in rapid presentation by both DCs and B cells within 6 hr of
subcutaneous injection, consistent with published reports (Itano et al., 2003; Pape et al., 2007).
Immunisation with antigen conjugated to 40 nm particles resulted in similar rapid presentation by DCs
(Figure 4A,B) and B cells (Figure 5A–C) as previously observed with soluble antigen (Itano et al., 2003;
Pape et al., 2007). An equivalent proportion of DCs also presented Eα/MHCII following immunisation with
200 nm particles. Percentages and numbers of Eα/MHCII positive DCs equivalent to soluble and
40 nm particle antigen formulations were detected at 24 and 48 hr. However, in contrast to soluble and
40 nm particle formulations, 200 nm particle challenge resulted in presentation of antigen beyond 48 hr,
with 21 ± 3% of conventional DCs staining positive for Eα/MHCII at 72 hr post immunisation (Figure 4C).
Presentation of antigen conjugated to 200 nm particles by the B cell compartment was slower
Figure 4. 200 nm particulate antigen challenge promotes sustained presentation of peptide/MHCII by dendritic
cells (DCs). C57BL/6 mice were immunized s.c. in the footpad with 100 μg of the model antigen EαGFP alone or
covalently conjugated to 40 nm or 200 nm particles. Challenge with PBS was included as a negative control. The
draining popliteal LNs were harvested after 1, 6, 24, 48 and 72 hr post challenge. Flow cytometry was used to
determine levels of presentation of the Eαpeptide/MHC class II complex using the monoclonal antibody YAe on
CD11c+B220− conventional DCs. The percentage and number of conventional DCs cells staining YAe+ is shown in
(A) and (B) respectively. Representative flow cytometry plots are shown for 72 hr post challenge (C). Data shows the
mean of three animals per time point ± standard deviation and are representative of ≥2 independent experiments.
* 40 nm vs 200 nm p = 0.012.
DOI: 10.7554/eLife.06994.007
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(Figure 5A–C) but did reach levels equivalent to soluble and 40 nm particle-bound antigen. The sustained
presentation observed by DCs was not evident in the B cell compartment (Figure 5D), with no significant
differences in B cell presentation being detected beyond 24 hr (Figure 5). Thus, larger particles did not
alter the magnitude of presentation but did prolong the duration of peptide/MHCII presentation by DCs.
Sustained peptide/MHCII presentation supports late T cell/DC
interactions
The relevance of antigen presentation at 72 hr induced by antigen conjugated to 200 nm particles was
questionable given evidence from intravital imaging studies. Such studies have demonstrated that
T cell priming by DCs occurs in three successive stages (Stoll et al., 2002; Bousso and Robey, 2003;
Mempel et al., 2004; Miller et al., 2004); stage 1 (0–8 hr) characterised by rapid T cell motility and
Figure 5. Peptide/MHCII presentation by B cells. C57BL/6 mice were immunized s.c. in the footpad with 100 μg of the
model antigen EαGFP alone or covalently conjugated to 40 nm or 200 nm particles. Challenge with PBS was included as
a negative control. The draining popliteal LNs were harvested after 1, 6, 24, 48 and 72 hr post challenge. Flow cytometry
was used to determine levels of presentation of the Eαpeptide/MHC class II complex using the monoclonal antibody YAe
on B220+CD11c− B cells. The percentage and number of conventional DCs cells staining YAe+ is shown in (A) and (B)
respectively. Representative flow cytometry plots are shown for 6 and 72 hr post challenge (C, D respectively). Data shows
the mean of three animals per time point ± standard deviation and are representative of ≥2 independent experiments.
DOI: 10.7554/eLife.06994.008
Benson et al. eLife 2015;4:e06994. DOI: 10.7554/eLife.06994 7 of 16
Research article Immunology
short T/DC interactions (2–3 min); stage 2 (12–24 hr) with long-term T/DC interactions associated with
the induction of priming and; stage 3 (48–72 hr) where T cells resume motility and short T/DC
interactions. We therefore examined the impact of particle size on stage 3 T cell/DC interactions in
vivo. CD11c-YFP recipients were adoptively transferred with OT-II DsRed T cells and challenged with
OVA conjugated 40 nm or 200 nm particles 72 hr before lymph node imaging by MPLSM (Video 1 and
Figure 6A). Multiple short duration T cell-DC interactions (2.149 ± 0.139 min) were observed with
40 nm OVA particles (Figure 6B), comparable to that seen with naı¨ve T cells and therefore consistent
with an absence of cognate peptide/MHC and classic stage 3 motility (Mempel et al., 2004). Notably,
interactions longer than 10 min were seen following 200 nm particle challenge (Figure 6B), implying
that antigen driven cognate recognition was still occurring. This was further supported by the reduced
T cell velocity observed in the 200 nm particle group (Figure 6C) and again in a lower T cell
displacement rate (Figure 6D). T cell migratory patterns within the LNs were not significantly different
between challenges as evidenced by their equivalent meandering indices (Figure 6E). Thus, the
antigen presentation by DCs at 72 hr post challenge induced by antigen-conjugated 200 nm particles
changed the dynamics of T cell/DC interactions, with stable, long-term interactions extending into the
stage 3 time period, conventionally associated with transient interactions and rapid T cell motility
(Hugues et al., 2004; Mempel et al., 2004; Miller et al., 2004; Zinselmeyer et al., 2005).
Antigen size influences Tfh differentiation by sustaining peptide/MHCII
presentation
Previous studies have demonstrated that differences in stage 2 interactions underlie the outcome of
the developing immune response, with long-term (>10 min) and short-term (<3 min) interactions
being associated with induction or priming and tolerance respectively (Hugues et al., 2004; Mempel
et al., 2004; Zinselmeyer et al., 2005). Significantly, the causal link between T cell behaviour and
function was subsequently revealed through disrupting TcR/pMHCII interactions with a monoclonal
antibody (Y3P), which resulted in of loss long-term T/DC contacts, a return to rapid T cell motility, and
a loss of T cell activation (Celli et al., 2007). We hypothesised that the long-term T/DC interactions we
observed at 72 hr post immunisation with 200 nm particles were responsible for selective Tfh
differentiation. To test this hypothesis, we employed the approach described by Celli et al (2007),
using the Y3P monoclonal antibody against MHCII (Celli et al., 2007) administered at 72 hr post
challenge. Disruption of TcR/pMHCII blocked the stable interactions between T cells and DCs
(Videos 1, 2, Figure 7A,B) and increased T cell motility (data not shown). Unlike blocking stage
2 T/DC interactions (Celli et al., 2007), robust T cell proliferative responses were observed with Y3P
treatment at 72 hr (Figure 7C). However, blocking MHCII at this time point did significantly reduce the
proportion of antigen specific cells co-expressing CXCR5 and PD-1 (Figure 7D,E). Therefore, we
conclude that while the sustained T/DC inter-
actions at 72 hr induced by 200 nm particles do
not increase the magnitude of the resulting
immune response, these interactions specifically
function to alter the quality of immune response
by promoting Tfh differentiation.
Analysis of antigen presentation kinetics fol-
lowing immunisation with 200 nm particles
revealed that at the time of MHCII blocking
(72 hr) the major population of APCs were DCs.
Our multiphoton studies further confirmed that
T cells were continuing to interact with DCs at
this time. However, interactions with antigen
presenting B cells could not be ruled out as
a contributing factor, especially given their
critical role in affirming and maintaining the Tfh
phenotype (Johnston et al., 2009; Crotty, 2011;
Baumjohann et al., 2013). To establish whether
the Tfh phenotype observed following immunisa-
tion with 200 nm particles was attributable purely
Video 1. Imaging DC and T cell behaviour after
challenge with 200 nm particulate antigen. DsRed OT-II
T cells were adoptively transferred into CD11cYFP
recipients and footpad challenged with 100 μg of OVA
conjugated to 40 nm or 200 nm particles. Popliteal LNs
were imaged at 72 hr. 2 hr prior to imaging,
200 nm challenged groups were given 500 μg mIgG2a
or Y3P (anti-mouse I-A). Data is representative of ≥3
individual animals and shows one of three separate
areas imaged per lymph node. Scale bar represents
50 μm.
DOI: 10.7554/eLife.06994.009
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to DC presentation at 72 hr we assessed Tfh differentiation in the absence of cognate pMHCII B cell
presentation. Immunisation of MD4 mice with 200 nm OVA particles induced equivalent proportional
increases in adoptively transferred OT-II T cells as seen in C57BL/6 mice (Figure 8A). Interestingly, the
Tfh phenotype induced following immunisation with 200 nm particles was not significantly altered in
the absence of cognate T-B cell interactions (Figure 8B). Inclusion of pMHCII blockade at 72 hr post
immunisation in MD4 mice did not influence expansion of the OT-II population (Figure 8A) but did
significantly reduce the proportion of cells co-expressing CXCR5 and PD-1 (Figure 8B), reaffirming
the importance of pMHCII recognition at this time. Taken together, the data implicates DCs rather
than B cells as the APC population mediating this effect.
Discussion
We have provided, in unprecedented detail, the spatiotemporal sequence of events that underlie
enhanced differentiation of Tfh cells, GC response and protective Ab production by antigen
formulations in vivo. By combining highly defined antigen delivery systems, with trackable antigen,
antigen-receptor transgenics (Tgs) and state of the art imaging techniques, we revealed that antigen
Figure 6. DC and T cell interactions persist after challenge with 200 nm particulate antigen. DsRed OT-II T cells were
adoptively transferred into CD11cYFP recipients and footpad challenged with 100 μg of OVA alone, conjugated to
40 nm or 200 nm particles. Popliteal LNs were imaged at 72 hr. Representative images following challenge (A) correspond
with Video 1 video file. The duration of OT-II T cell interaction with DCs was determined as intersection of DsRed and YFP
signals (B). The velocity (C), displacement rate (D) and meandering index (E) for T cells were calculated. Data is
representative of ≥3 individual animals and shows pooled tracks with mean values of three separate areas of a lymph
node. Scale bars represent 50 μm.
DOI: 10.7554/eLife.06994.010
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size impacts on the duration of peptide/MHCII
presentation and the maintenance beyond 48 hr
of functional DC and T cell interactions in the
draining LN. The functional relevance of longer
DC-T cell interactions, associated with antigen
conjugated to 200 nm particles, was dissected by
specifically blocking later interactions, resulting
in reduced Tfh induction, while the overall
magnitude of the T cell response was unaffected.
Thus, the temporal characteristics of T cell
stimulation can determine their functional differ-
entiation towards a Tfh phenotype, and this can
be determined by the size of the particle upon
which an antigen is delivered.
Previous studies have investigated the impact
of particle size on the immune response to
antigen using a variety of formulations, for
example lipid vesicles entrapping (Brewer
et al., 2004; Moon et al., 2012) antigens or antigens non-specifically adsorbed to the surface of
inert particles (Mottram et al., 2007). The inert nature, defined size and surface functionalisation of
particles employed in the present study, allowed a single variable, size, to be tested for its impact on
antigen immunogenicity. Initial studies simply altering particle size revealed 200 nm particles could
induce antibody production following a single immunisation. The functional importance of this
observation was startlingly clear, with 200 nm particles able to impart protective anti-HA humoral
immunity to influenza infection. Starting with a functional outcome relevant to vaccine design, we
sought to dissect the processes by which increasing particle size impacts on the humoral response.
GC formation is central to development of high affinity antibody. GC structures support somatic
hypermutation, selection of high affinity B cells and their differentiation into plasma and memory cells
(for a comprehensive review seeVictora andNussenzweig, 2012). Immunisation with 200 nm particles
enhanced this process, explaining our initial observation of increased antibody responses. Essential in
this process is the cognate interaction between Ag-specific B and T cells. The nature of this interaction
has been the focus of intense research in recent years, culminating in the identification of Tfh cells and
the molecules (surface and soluble) involved in their differentiation and function (Ma et al., 2012).
While both sizes of particle could equally increase antigen specific T cell responses in vivo, we found
that larger particles (200 nm) induced greater Tfh differentiation than small (40 nm) particles,
consistent with their role in supporting GC responses. Even though the endogenous molecular cues
governing the development of Tfh cells are multifactorial (Crotty, 2011; Ma et al., 2012),
understanding how external stimuli can influence T cell differentiation towards this phenotype is
less well understood, yet has clear implications in vaccine design. In this case we have demonstrated
that simply changing the size of the Ag can clearly impact on Tfh differentiation.
A key event in the initiation of any CD4+ T cell response is the recognition of peptide/MHC class II
complexes on DCs. The kinetics of presentation are known to influence the consequent CD4+ T cell
proliferative, effector and memory responses induced (Obst et al., 2005, 2007; Celli et al., 2007). By
covalently linking a trackable antigen to the particles we were able to map temporally in vivo peptide/
MHC class II presentation and its relation to particle size. Although 200 nm particle immunisation
prolonged the duration of peptide/MHC class II presentation by DCs, significantly this did not impact
upon the magnitude of the T cell response compared with the smaller 40 nm particle, consistent with
a previous report (Gengoux and Leclerc, 1995). However, prolonged presentation was associated
with the enhanced differentiation of Tfh cells. Antigen availability can dictate the magnitude of a Tfh
response, with sustained presentation by B cells maintaining the Tfh phenotype (Baumjohann et al.,
2013). Notably, immunisation with 200 nm particles resulted in sustained antigen presentation by DCs
with cognate interactions with B cells being dispensable for maintenance of a Tfh phenotype. Indeed,
sustained antigen presentation associated with Tfh induction has been reported in the absence of
cognate interactions with B cells (Deenick et al., 2010). In the latter study, CD4+ T cells deficient for
SAP, and therefore limited in their ability to interact with B cells, still adopted a Tfh phenotype when
a second dose of soluble antigen was given 72 hr later. Presentation at this second challenge was
Video 2. Disruption of DC and T cell interactions using
Y3P. As for Video 1, DsRed OT-II T cells were adoptively
transferred into CD11cYFP recipients and footpad
challenged with 100 μg of OVA conjugated to 40 nm or
200 nm particles. Popliteal LNs were imaged at 72 hr.
2 hr prior to imaging, 200 nm challenged groups were
given 500 μg mIgG2a or Y3P (anti-mouse I-A). Videos
were acquired using a 20×/1.0 NA water-immersion
objective lens and 2× zoom. Areas of interaction are
shown in grey. Scale bars represent 25 μm.
DOI: 10.7554/eLife.06994.011
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Figure 7. Blockade of stage 3 DC/T cell interactions following 200 nm particulate challenge prevents Tfh differentiation. Disruption of stage 3 DC/T cell
interaction was demonstrated by imaging DsRed OT-II T cells adoptively transferred into CD11cYFP recipients. Mice were footpad challenged with 100 μg
of OVA conjugated to 200 nm particles and popliteal LNs imaged at 72 hr. 500 μg isotype (mIgG2a) or Y3P (anti-mouse I-A) was given i.v. 2 hr prior to
imaging. Representative video frames show areas of intersection in grey and highlighted by white arrows (A, see Video 2 for video). Scale bars represent
25 μm. The duration of OT-II T cell interaction with DCs was determined as intersection of DsRed and YFP signals (B). Next, CFSE OT-II TcR Tg T cells were
adoptively transferred into C57BL/6 recipients. Mice were then challenged with PBS, OVA with CFA or OVA conjugated to 200 nm particles. Mice were
treated with a single dose of Y3P or isotype antibody i.v. 72 hr post challenge with particles. Draining LNs were harvested on day 5 post challenge.
(C) Representative plots showing CFSE division of CD45.1+OT-II TcR Tg T cells (gated on CD4+ population). Tfh cells were defined as being PD-1+CXCR5+
(D) and confirmed as ICOS+ (data not shown) for plotting Tfh proportion as a percentage of the OT-II population (E). Data is representative of two
independent experiments with five animals per group.
DOI: 10.7554/eLife.06994.012
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attributed to DCs (Deenick et al., 2010), consistent with our own findings. Indeed, DCs can induce Tfh
development in the absence of cognate interactions with B cells (Choi et al., 2011) and likely
represent the first step initiating Tfh differentiation (Goenka et al., 2011). Imaging draining LNs 72 hr
post challenge revealed that cognate T cell/DC interactions continued at this time. Importantly the
current study adds mechanistic detail to the observational data above; temporal disruption of 72 hr
(stage 3) interactions, while not affecting clonal expansion, did inhibit 200 nm particle induced Tfh
differentiation. Thus, increasing particle size, and sustaining presentation by DCs and their cognate
interactions with T cells underpins the success of the larger particle in driving Tfh differentiation. It is
unclear as to how particle size influences temporal availability of pMHCII on DCs. Particulates can
impact on the mechanism of antigen uptake and therefore consequent endosomal targeting,
processing and dynamics of presentation (De Temmerman et al., 2011; Zhao et al., 2011; Ghimire
et al., 2012). Thus the processing of antigen and loading of MHCII and/or its turnover at the cell
surface may be contributing factors. In either case, increasing availability of TcR ligand and
consequent TcR signal quantity may function in a similar way as increasing TcR dwell time in
determining Tfh differentiation (Tubo et al., 2013; Tubo and Jenkins, 2014).
New delivery systems are required to generate safe and effective vaccines. This has resulted in
increased focus on particle delivery systems. Our findings provide mechanistic insight as to why some
formulations promote humoral immunity while others do not (Mottram et al., 2007;Moon et al., 2012).
We have linked T cell behaviour to function, demonstrating the importance of stage 3 T/DC interactions
in determining the selective differentiation of T cells towards a Tfh lineage. These late stage interactions
could be selectively induced using immunisation with antigen conjugated to 200 nm but not
40 nm particles, rationalising approaches to vaccine design using nanoparticles for induction of Tfh, GC
formation and high affinity, class switched protective antibody. Previous studies have demonstrated that
in the absence of microbial factors, parameters such as the dose and persistence of antigen can affect
T cell differentiation (Constant and Bottomly, 1997). The current data therefore explain why
parameters such as the magnitude and duration of antigen presentation affect subsequent T/DC
interactions and consequently determine T cell differentiation in the developing immune response.
Materials and methods
Animals
hCD2-DsRed mice (gifted by D Kioussis and A Patel, National Institute for Medical Research, London)
were crossed with OVA specific OT-II (Barnden et al., 1998) TCR Tg mice. MD4 BcR Tg mice
(Mason et al., 1992) on C57BL/6 backgrounds were used as a source of HEL specific B cells. 6–8 week
old C57BL/6J mice were used as recipients (Harlan, Bicester, UK). CD11c-YFP mice (Lindquist et al., 2004)
Figure 8. Cognate interactions between B and T cells are not required for early Tfh differentiation. OT-II TcR Tg
T cells and were adoptively transferred into C57BL/6 or intact MD4 BcR Tg recipients. Mice were then challenged
with OVA conjugated to 200 nm particles and 500 μg isotype (mIgG2a) or Y3P (anti-mouse I-A) given i.v. 72 hr later.
Challenges with PBS, OVA/CFA were included as negative and positive controls. Flow cytometry was used to assess
CD4+CD45.1+ OT-II cell expansion in LNs 5 days post challenge (A). Tfh were defined by PD-1 and CXCR5 co-
expression (B). Panels show mean value and five individual animals, ***p < 0.001.
DOI: 10.7554/eLife.06994.013
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were used a recipients in multiphoton imaging experiments. All animals were specified pathogen free and
maintained under standard animal house conditions at the University of Glasgow in accordance with UK
Home Office Regulations.
Antigen and bead preparations
The recombinant HA protein used was expressed from DNA encoding the extracellular domain of the
influenza A virus subtype H1N1 (A/WSN/1933) HA (Life Technologies, Paisley, UK). OVA-HEL
conjugates were prepared using gluteraldehyde to couple the chicken OVA (Worthington
Biochemical, Lakewood, NJ, USA) and HEL (BBI Enzymes, Gwent, UK) as published (Garside et al.,
1998). EαGFP was produced in house as detailed previously (Rush and Brewer, 2010). HA, OVA,
OVA-HEL or EαGFP were covalently bound to Polybead Carboxylate Microspheres (Park Scientific,
Northampton, UK). Briefly, carboxylate-modified nanospheres were incubated with 2.5 mg/ml protein
(EαGFP, HA, OVA or OVA-HEL) with 1 mM EDAC (1-ethyl-3-(3-dimethylaminopropyl) carbodiimide;
Sigma, Dorset, UK) and 25 mM MES (2-N-morpholino ethane sulfonic acid; Sigma) overnight, in line
with manufacturers instructions. Conjugation mixes were then spun in an ultracentrifuge at 4˚C for 40
min. Protein concentration in the supernatant was measured to allow the amount bound to the
microspheres to be calculated. Preparations were stored at 4˚C and used within 3 days of preparation.
Infection with influenza virus
Mice were immunized subcutaneously (s.c.) in the scruff. Infections with influenza virus subtype H1N1
A/WSN/1933 (WSN) were carried out in mice anesthetized with isofluorane and 20 μl of PBS
containing 300 PFU of WSN virus administered intranasally (5 mice per group). This dose was used as
previous experiments showed that this dose led to approximately 20% weight loss in unvaccinated
animals. Viral stocks were prepared and titred in MDCK cells.
Adoptive transfer of antigen specific lymphocytes and in vivo challenge
Adoptive transfers were performed as described previously (Smith et al., 2000). Briefly, single cell
suspensions of LNs and spleens were prepared from OT-II and MD4 mice. The proportion of Tg B and
T cells was determined by flow cytometry and 2–3 × 106 Tg B cells and 2–3 × 106 Tg T cells adoptively
transferred to age-matched C57BL/6J recipients via tail vein injection. For imaging studies, DsRed
expressing CD4+ OT-II T cells were magnetically sorted from OT-II × hCD2-DsRed animals using
mouse CD4+ T cell isolation kits (Miltenyi Biotec, Surrey, UK). Mice were immunized via the footpad
with 130 μg of OVA-HEL conjugate alone, with CFA (Sigma, Dorset, UK), or covalently bound to
carboxylate-modified microspheres. Injection with 50 μl of PBS was used as a vehicle control. Popliteal
LNs were excised for ex vivo study. In MHCII blocking experiments, 500 μg Y3P (BioXcell, New
Hampshire, USA) or isotype control (mouse IgG2a; BioXcell) was given via tail vein injection. In T cell/DC
interaction studies, LNs were imaged 2 hr after antibody treatment.
Flow cytometry
Single cell suspensions were stained using combinations of anti-CD11c-PE (N418, BD Biosciences, San
Jose, CA, USA), anti-B220-PerCP (RA3-6B2, BD Biosciences), anti-I-Ab/Ea52-68-biotin (YAe, eBio-
science, San Diego, CA, USA), anti-CD4-eFluor450 (RM4-5, eBioscience), anti-ICOS-alexa-fluor-488
(C398.4A, BioLegend, San Diego, CA, USA), anti-PD-1-PE-Cy7 (J43, eBiosciences), anti-SLAM-APC
(TC15-12F12.2, BioLegend), biotinylated anti-CXCR5 (2G8, BD Biosciences), anti-B220-eFluor450
(RA3-6B2, eBioscience), anti-GL-7-FITC (BD Biosciences), anti-FAS-PE (BD Biosciences) and biotinylated
anti-IgMa (DM-1, BD Biosciences). Biotinylated antibodies were detected by incubation with
fluorochrome-conjugated streptavidin (BD Biosciences). Appropriate isotype controls were used
throughout. Samples were acquired using a MACSQuant analyzer (Miltenyi Biotec, Surrey, UK) and
analysed using FlowJo software (Tree Star Inc, Ashland, OR, USA).
Multiphoton imaging
Multiphoton imaging was carried out using a Zeiss LSM7 MP system equipped with a 20×/1.0 NA
water-immersion objective lens (Zeiss UK, Cambridge, UK) and a tunable Titanium: sapphire solid-
state two-photon excitation source (Chameleon Ultra II; Coherent Laser Group, Glasgow, UK) and
optical parametric oscillator (OPO; Coherent Laser Group). Excised LNs were continuously bathed in
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warmed (37˚C), oxygenated CO2 independent medium. A laser output of 820 nm and OPO signal at
1060 nm provided excitation of YFP CD11c+ and DsRed OT-II cells. Videos were acquired for 20 to
30 min with an X-Y pixel resolution of 512 × 512 in 2 μm Z increments. 3D tracking was performed
using Volocity 6.1.1 (Perkin Elmer, Cambridge, UK). Values representing the mean velocity,
displacement, and meandering index were calculated for each object. The intersection of DsRed
and YFP objects was used to determine interaction between T cells and DCs respectively.
Statistics
Results are expressed as mean ± standard deviation. Gaussian distribution was confirmed by
D’Agostino & Pearson omnibus normality test prior to significance being determined by one-way
ANOVA. Significance in DC-T cell interaction experiments was confirmed by Mann Whitney. Values of
p < 0.05 were regarded as significant.
Acknowledgements
This work was supported by the Wellcome Trust (Grant Number WT085589MA). BGH is a Sir Henry
Dale Fellow jointly funded by the Wellcome Trust and the Royal Society (Grant Number 100034/Z/12/Z).
The authors declare no competing financial interests.
Additional information
Funding
Funder Grant reference Author
Wellcome Trust WT085589MA Paul Garside, James M Brewer
Wellcome Trust 100034/Z/12/Z Megan KL MacLeod
The funder had no role in study design, data collection and interpretation, or the
decision to submit the work for publication.
Author contributions
RAB, Acquisition of data, Analysis and interpretation of data, Drafting or revising the article; MKLML,
Analysis and interpretation of data, Drafting or revising the article, Contributed unpublished
essential data or reagents; BGH, Conception and design, Acquisition of data, Analysis and
interpretation of data; AP, PG, Conception and design, Analysis and interpretation of data, Drafting
or revising the article; JMB, Conception and design, Acquisition of data, Analysis and interpretation
of data, Drafting or revising the article
Author ORCIDs
James M Brewer, http://orcid.org/0000-0001-7933-0915
Ethics
Animal experimentation: All animals were specified pathogen free and maintained under standard
animal house conditions at the University of Glasgow in accordance with local and UK Home Office
Regulations.
References
Barnden MJ, Allison J, Heath WR, Carbone FR. 1998. Defective TCR expression in transgenic mice constructed
using cDNA-based alpha- and beta-chain genes under the control of heterologous regulatory elements.
Immunology and Cell Biology 76:34–40. doi: 10.1046/j.1440-1711.1998.00709.x.
Baumjohann D, Preite S, Reboldi A, Ronchi F, Ansel KM, Lanzavecchia A, Sallusto F. 2013. Persistent antigen and
germinal center B cells sustain T follicular helper cell responses and phenotype. Immunity 38:596–605. doi: 10.
1016/j.immuni.2012.11.020.
Bousso P, Robey E. 2003. Dynamics of CD8+ T cell priming by dendritic cells in intact lymph nodes. Nature
Immunology 4:579–585. doi: 10.1038/ni928.
Brewer JM, Pollock KG, Tetley L, Russell DG. 2004. Vesicle size influences the trafficking, processing, and
presentation of antigens in lipid vesicles. The Journal of Immunology 173:6143–6150. doi: 10.4049/jimmunol.
173.10.6143.
Benson et al. eLife 2015;4:e06994. DOI: 10.7554/eLife.06994 14 of 16
Research article Immunology
Brewer JM. 2006. (How) do aluminium adjuvants work? Immunology Letters 102:10–15. doi: 10.1016/j.imlet.2005.
08.002.
Celli S, Lemaitre F, Bousso P. 2007. Real-time manipulation of T cell-dendritic cell interactions in vivo reveals the
importance of prolonged contacts for CD4+ T cell activation. Immunity 27:625–634. doi: 10.1016/j.immuni.2007.08.018.
Choi YS, Kageyama R, Eto D, Escobar TC, Johnston RJ, Monticelli L, Lao C, Crotty S. 2011. ICOS receptor instructs
T follicular helper cell versus effector cell differentiation via induction of the transcriptional repressor Bcl6.
Immunity 34:932–946. doi: 10.1016/j.immuni.2011.03.023.
Constant SL, Bottomly K. 1997. Induction of Th1 and Th2 CD4+ T cell responses: the alternative approaches.
Annual Review of Immunology 15:297–322. doi: 10.1146/annurev.immunol.15.1.297.
Crotty S. 2011. Follicular helper CD4 T cells (TFH). Annual Review of Immunology 29:621–663. doi: 10.1146/
annurev-immunol-031210-101400.
De Temmerman ML, Rejman J, Demeester J, Irvine DJ, Gander B, De Smedt SC. 2011. Particulate vaccines: on the
quest for optimal delivery and immune response. Drug Discovery Today 16:569–582. doi: 10.1016/j.drudis.2011.
04.006.
Deenick EK, Chan A, Ma CS, Gatto D, Schwartzberg PL, Brink R, Tangye SG. 2010. Follicular helper T cell
differentiation requires continuous antigen presentation that is independent of unique B cell signaling. Immunity
33:241–253. doi: 10.1016/j.immuni.2010.07.015.
Fazilleau N, McHeyzer-Williams LJ, Rosen H, McHeyzer-Williams MG. 2009. The function of follicular helper T cells
is regulated by the strength of T cell antigen receptor binding. Nature Immunology 4:375–384. doi: 10.1038/ni.
1704.
Garside P, Ingulli E, Merica RR, Johnson JG, Noelle RJ, Jenkins MK. 1998. Visualization of specific B and
T lymphocyte interactions in the lymph node. Science 281:96–99. doi: 10.1126/science.281.5373.96.
Gengoux C, Leclerc C. 1995. In vivo induction of CD4+ T cell responses by antigens covalently linked to synthetic
microspheres does not require adjuvant. International Immunology 7:45–53. doi: 10.1093/intimm/7.1.45.
GerhardW. 2001. The role of the antibody response in influenza virus infection. Current Topics in Microbiology and
Immunology 260:171–190.
Ghimire TR, Benson RA, Garside P, Brewer JM. 2012. Alum increases antigen uptake, reduces antigen degradation
and sustains antigen presentation by DCs in vitro. Immunology Letters 147:55–62. doi: 10.1016/j.imlet.2012.
06.002.
Goenka R, Barnett LG, Silver JS, O’Neill PJ, Hunter CA, Cancro MP, Laufer TM. 2011. Cutting edge: dendritic cell-
restricted antigen presentation initiates the follicular helper T cell program but cannot complete ultimate effector
differentiation. The Journal of Immunology 187:1091–1095. doi: 10.4049/jimmunol.1100853.
Hugues S, Fetler L, Bonifaz L, Helft J, Amblard F, Amigorena S. 2004. Distinct T cell dynamics in lymph nodes
during the induction of tolerance and immunity. Nature Immunology 5:1235–1242. doi: 10.1038/ni1134.
Itano AA, McSorley SJ, Reinhardt RL, Ehst BD, Ingulli E, Rudensky AY, Jenkins MK. 2003. Distinct dendritic cell
populations sequentially present antigen to CD4 T cells and stimulate different aspects of cell-mediated
immunity. Immunity 19:47–57. doi: 10.1016/S1074-7613(03)00175-4.
Johnston RJ, Poholek AC, DiToro D, Yusuf I, Eto D, Barnett B, Dent AL, Craft J, Crotty S. 2009. Bcl6 and Blimp-1
are reciprocal and antagonistic regulators of T follicular helper cell differentiation. Science 325:1006–1010.
doi: 10.1126/science.1175870.
Karlson Tde L, Kong YY, Hardy CL, Xiang SD, Plebanski M. 2013. The signalling imprints of nanoparticle uptake by
bone marrow derived dendritic cells. Methods 60:275–283. doi: 10.1016/j.ymeth.2013.02.009.
Knossow M, Skehel JJ. 2006. Variation and infectivity neutralization in influenza. Immunology 119:1–7. doi: 10.
1111/j.1365-2567.2006.02421.x.
Lindquist RL, Shakhar G, Dudziak D, Wardemann H, Eisenreich T, Dustin ML, Nussenzweig MC. 2004. Visualizing
dendritic cell networks in vivo. Nature Immunology 5:1243–1250. doi: 10.1038/ni1139.
Linterman MA, Rigby RJ, Wong R, Silva D, Withers D, Anderson G, Verma NK, Brink R, Hutloff A, Goodnow CC,
Vinuesa CG. 2009. Roquin differentiates the specialized functions of duplicated T cell costimulatory receptor
genes CD28 and ICOS. Immunity 30:228–241. doi: 10.1016/j.immuni.2008.12.015.
Ma CS, Deenick EK, Batten M, Tangye SG. 2012. The origins, function, and regulation of T follicular helper cells.
The Journal of Experimental Medicine 209:1241–1253. doi: 10.1084/jem.20120994.
Manolova V, Flace A, Bauer M, Schwarz K, Saudan P, Bachmann MF. 2008. Nanoparticles target distinct dendritic
cell populations according to their size. European Journal of Immunology 38:1404–1413. doi: 10.1002/eji.
200737984.
Mason DY, Jones M, Goodnow CC. 1992. Development and follicular localization of tolerant B lymphocytes in
lysozyme/anti-lysozyme IgM/IgD transgenic mice. International Immunology 4:163–175. doi: 10.1093/intimm/4.
2.163.
Mempel TR, Henrickson SE, Von Andrian UH. 2004. T-cell priming by dendritic cells in lymph nodes occurs in three
distinct phases. Nature 427:154–159. doi: 10.1038/nature02238.
Miller MJ, Safrina O, Parker I, Cahalan MD. 2004. Imaging the single cell dynamics of CD4+ T cell activation by
dendritic cells in lymph nodes. The Journal of Experimental Medicine 200:847–856. doi: 10.1084/jem.20041236.
Moon JJ, Suh H, Li AV, Ockenhouse CF, Yadava A, Irvine DJ. 2012. Enhancing humoral responses to a malaria
antigen with nanoparticle vaccines that expand Tfh cells and promote germinal center induction. Proceedings of
the National Academy of Sciences of USA 109:1080–1085. doi: 10.1073/pnas.1112648109.
Mottram PL, Leong D, Crimeen-Irwin B, Gloster S, Xiang SD, Meanger J, Ghildyal R, Vardaxis N, Plebanski M.
2007. Type 1 and 2 immunity following vaccination is influenced by nanoparticle size: formulation of a model
vaccine for respiratory syncytial virus. Molecular Pharmaceutics 4:73–84. doi: 10.1021/mp060096p.
Benson et al. eLife 2015;4:e06994. DOI: 10.7554/eLife.06994 15 of 16
Research article Immunology
Murphy BR, Nelson DL, Wright PF, Tierney EL, Phelan MA, Chanock RM. 1982. Secretory and systemic
immunological response in children infected with live attenuated influenza A virus vaccines. Infection and
Immunity 36:1102–1108.
Nurieva RI, Chung Y, Hwang D, Yang XO, Kang HS, Ma L, Wang YH, Watowich SS, Jetten AM, Tian Q, Dong C.
2008. Generation of T follicular helper cells is mediated by interleukin-21 but independent of T helper 1, 2, or 17
cell lineages. Immunity 29:138–149. doi: 10.1016/j.immuni.2008.05.009.
Nutt SL, Tarlinton DM. 2011. Germinal center B and follicular helper T cells: siblings, cousins or just good friends?
Nature Immunology 12:472–477. doi: 10.1038/ni.2019.
Obst R, van Santen HM, Mathis D, Benoist C. 2005. Antigen persistence is required throughout the expansion
phase of a CD4(+) T cell response. The Journal of Experimental Medicine 201:1555–1565. doi: 10.1084/jem.
20042521.
Obst R, van Santen HM, Melamed R, Kamphorst AO, Benoist C, Mathis D. 2007. Sustained antigen presentation
can promote an immunogenic T cell response, like dendritic cell activation. Proceedings of the National Academy
of Sciences of USA 104:15460–15465. doi: 10.1073/pnas.0707331104.
Owens T, Zeine R. 1989. The cell biology of T-dependent B cell activation. Biochemistry and Cell Biology 67:
481–489. doi: 10.1139/o89-078.
Pape KA, Catron DM, Itano AA, Jenkins MK. 2007. The humoral immune response is initiated in lymph nodes by
B cells that acquire soluble antigen directly in the follicles. Immunity 26:491–502. doi: 10.1016/j.immuni.2007.
02.011.
Rush CM, Brewer JM. 2010. Tracking dendritic cells in vivo. Methods in Molecular Biology 626:169–185. doi: 10.
1007/978-1-60761-585-9_12.
Smith KM, Pottage L, Thomas ER, Leishman AJ, Doig TN, Xu D, Liew FY, Garside P. 2000. Th1 and Th2 CD4+
T cells provide help for B cell clonal expansion and antibody synthesis in a similar manner in vivo. The Journal of
Immunology 165:3136–3144. doi: 10.4049/jimmunol.165.6.3136.
Stoll S, Delon J, Brotz TM, Germain RN. 2002. Dynamic imaging of T cell-dendritic cell interactions in lymph nodes.
Science 296:1873–1876. doi: 10.1126/science.1071065.
Tubo NJ, Jenkins MK. 2014. TCR signal quantity and quality in CD4 T cell differentiation. Trends in Immunology 35:
591–596. doi: 10.1016/j.it.2014.09.008.
Tubo NJ, Paga´n AJ, Taylor JJ, Nelson RW, Linehan JL, Ertelt JM, Huseby ES, Way SS, Jenkins MK. 2013. Single
naive CD4+ T cells from a diverse repertoire produce different effector cell types during infection. Cell 153:
785–796. doi: 10.1016/j.cell.2013.04.007.
Victora GD, Nussenzweig MC. 2012. Germinal centers. Annual Review of Immunology 30:429–457. doi: 10.1146/
annurev-immunol-020711-075032.
Xiang SD, Scholzen A, Minigo G, David C, Apostolopoulos V, Mottram PL, Plebanski M. 2006. Pathogen
recognition and development of particulate vaccines: does size matter? Methods 40:1–9. doi: 10.1016/j.ymeth.
2006.05.016.
Xu H, Li X, Liu D, Li J, Zhang X, Chen X, Hou S, Peng L, Xu C, Liu W, Zhang L, Qi H. 2013. Follicular T-helper cell
recruitment governed by bystander B cells and ICOS-driven motility. Nature 496:523–527. doi: 10.1038/
nature12058.
Zhao F, Zhao Y, Liu Y, Chang X, Chen C, Zhao Y. 2011. Cellular uptake, intracellular trafficking, and cytotoxicity of
nanomaterials. Small 7:1322–1337. doi: 10.1002/smll.201100001.
Zinselmeyer BH, Dempster J, Gurney AM, Wokosin D, Miller M, Ho H, Millington OR, Smith KM, Rush CM, Parker
I, Cahalan M, Brewer JM, Garside P. 2005. In situ characterization of CD4+ T cell behavior in mucosal and
systemic lymphoid tissues during the induction of oral priming and tolerance. The Journal of Experimental
Medicine 201:1815–1823. doi: 10.1084/jem.20050203.
Benson et al. eLife 2015;4:e06994. DOI: 10.7554/eLife.06994 16 of 16
Research article Immunology
